Skip to main content
SpringerLink
Log in

Die (Krypto-)Pyrrolurie in der Umweltmedizin: eine valide Diagnose?

Mitteilung der Kommission „Methoden und Qualitätssicherung in der Umweltmedizin“

  • Empfehlung des Robert Koch-Instituts
  • Published:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Irvine DG (1961) Apparently non-indolic Ehrlichpositive substances related to mental illnesses. J Neuropsychiatr 2:292–305

    PubMed  CAS  Google Scholar 

  2. Hoffer A, Osmond H (1963) Malvaria: a new psychiatric disease. Acta Psychiatr Scand 39:335–366

    Article  PubMed  CAS  Google Scholar 

  3. Irvine DG, Bayne W, Miyashita H, et al. (1969) Identification of kryptopyrrole in human urine and its relation to psychosis. Nature 224(5221):811–883

    Article  PubMed  CAS  Google Scholar 

  4. Gendler PL, Duhan HA, Rapoport H (1978) Hemopyrrole and kryptopyrrole are absent from the urine of schizophrenics and normal persons. Clin Chem 24(2):230–233

    PubMed  CAS  Google Scholar 

  5. Jacobson SJ, Rapoport H, Ellman GL (1975) The nonoccurrence of hemo- and kryptopyrrole in urine of schizophrenics. Biol Psychiatry 10(1):91–93

    PubMed  CAS  Google Scholar 

  6. Pfeiffer CC, Sohler A, Jennery C, et al. (1974) Treatment of pyroluric schizophrenica with large doses of pyridoxine and a dietary supplement of zinc. J Orthomol Psychiatr 3:292–300

    Google Scholar 

  7. Irvine DG, Bayne W, Majer JR (1970) Autotransfer chromatography combined with mass spectroscopy, for the characterization of pyrroles and indoles. J Chromatogr 48(2):334–342

    Article  PubMed  CAS  Google Scholar 

  8. Sohler A, Beck R, Noval JJ (1970) Mauve factor re-identified as 2,4-dimethyl-3-ethylpyrrole and its sedative effect on the CNS. Nature 228(5278):1318–1320

    Article  PubMed  CAS  Google Scholar 

  9. Irvine DG, Wetterberg L (1972) Kryptopyrrole-like substance in acute intermittent porphyria. Lancet 2(7788):1201

    Article  PubMed  CAS  Google Scholar 

  10. Irvine DG (1974) Kryptopyrrole and other monopyrroles in molecular neurobiology. Int Rev Neurobiol 16:145–182

    PubMed  CAS  Google Scholar 

  11. Lightner DA, Crandall DC (1973) The dye sensitized photooxygenation of kryptopyrrole. Experientia 29(3):262–264

    Article  PubMed  CAS  Google Scholar 

  12. Irvine DG (1976) Autotransfer chromatography in the characterization of pyrroles. Chemistry of multiple-spot phenomena. J Chromatogr 123(1):69–78

    Article  PubMed  CAS  Google Scholar 

  13. Moore MR, Graham DJ (1980) Monopyrroles in porphyria, psychosis and lead exposure. Int J Biochem 12(5–6):827–832

    Article  PubMed  CAS  Google Scholar 

  14. Russell CS (1972) Biosynthesis of porphyrins and the origin of the “mauve factor”. J Theor Biol 35(2):277–283

    Article  PubMed  CAS  Google Scholar 

  15. Thomas L (2005) Porphyrien. In: Thomas L (Hrsg) Labor und Diagnose. TH-Books, Frankfurt:, S 646–659

  16. Brodie MJ, Graham DJ, Thompson GG, et al. (1976) The porphyrinogenic effects of kryptopyrrole in the rat and the occurrence of urinary kryptopyrrole in human hereditary hepatic porphyria. Clin Sci Mol Med 50(5):431–434

    PubMed  CAS  Google Scholar 

  17. Gorchein A (1980) Urine concentration of 3-ethyl- 5-hydroxy-4,5-dimethyl-delta 3-pyrrolin-2-one („mauve factor“) is not causally related to schizophrenia or to acute intermittent porphyria. Clin Sci (Lond) 58(6):469–476

    CAS  Google Scholar 

  18. Huszak I, Durko I, Karsai K (1972) Experimental data to the pathogenesis of cryptopyrrole excretion in schizophrenia I. Acta Physiol Acad Sci Hung 42(1):79–86

    PubMed  CAS  Google Scholar 

  19. Durko I, Berek I, Huszak I (1975) Effects of kryptopyrrole on porphyrin synthesis in Bacillus subtilis 168. Hoppe Seylers Z Physiol Chem 356(11):1679–1684

    PubMed  CAS  Google Scholar 

  20. Seyfried H, Klicpera M, Leithner C, et al. (1976) Bilirubin metabolism (author's transl). Wien Klin Wochenschr 88(15):477–482

    PubMed  CAS  Google Scholar 

  21. Oates PS, West AR (2006) Heme in intestinal epithelial cell turnover, differentiation, detoxification, inflammation, carcinogenesis, absorption and motility. World J Gastroenterol 12(27):4281–4295

    PubMed  CAS  Google Scholar 

  22. Cruz R, Vogel WH (1978) Pyroluria: a poor marker in chronic schizophrenia. Am J Psychiatry 135(10):1239–1240

    PubMed  CAS  Google Scholar 

  23. Ellman GL, Jones RT, Rychert RC (1968) Mauve spot and schizophrenia. Am J Psychiatry 125(6):849–851

    PubMed  CAS  Google Scholar 

  24. Brodie MJ, Moore MR, Goldberg A (1977) Enzyme abnormalities in the porphyrias. Lancet 2(8040):699–701

    Article  PubMed  CAS  Google Scholar 

  25. Dombeck TA, Satonik RC (2005) The porphyrias. Emerg Med Clin North Am 23(3):885–899

    Article  PubMed  Google Scholar 

  26. Ellefson RD, Ford RE (1996) The porphyrias [corrected]: characteristics and laboratory tests. Regul Toxicol Pharmacol 24(1 Pt 2):119–125

    Article  Google Scholar 

  27. Daniell WE, Stockbridge HL, Labbe RF, et al. (1997) Environmental chemical exposures and disturbances of heme synthesis. Environ Health Perspect 105(Suppl 1):37–53

    Article  PubMed  CAS  Google Scholar 

  28. Doss MO, Kuhnel A, Gross U (2000) Alcohol and porphyrin metabolism. Alcohol Alcohol 35(2):109–125

    PubMed  CAS  Google Scholar 

  29. Aust SD, Millis CD, Holcomb L (1987) Relationship of basic research in toxicology to environmental standard setting: the case of polybrominated biphenyls in Michigan. Arch Toxicol 60(1–3):29–237

    Article  Google Scholar 

  30. Campbell BC, Brodie MJ, Thompson GG, et al. (1977) Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. Clin Sci Mol Med 53(4):335–340

    PubMed  CAS  Google Scholar 

  31. Gorchein A (2002) Testing for porphobilinogen in urine. Clin Chem 48(3):564–566

    PubMed  CAS  Google Scholar 

  32. Maschewsky W (1996) MCS und Porphyrinopathien. Ztg Umweltmed 3:102–106

    Google Scholar 

  33. Silbergeld EK (1987) Porphyrins as indicators of chemical injury and exposure. Ann N Y Acad Sci 514:170–171

    Article  PubMed  CAS  Google Scholar 

  34. Silbergeld EK (1987) Role of altered heme synthesis in chemical injury to the nervous system. Ann N Y Acad Sci 514:297–308

    Article  PubMed  CAS  Google Scholar 

  35. Ziem G, McTamney J (1997) Profile of patients with chemical injury and sensitivity. Environ Health Perspect 105(Suppl 2):417–436

    Article  PubMed  Google Scholar 

  36. Baker GP (1995) Porphyria and MCS symptoms overlap – another chemical connection. Townsend Letter Doctors 144:72–73

    Google Scholar 

  37. Downey D (1996) Porphyria: a new perspective. Med Hypotheses 46(4):378–382

    Article  PubMed  CAS  Google Scholar 

  38. Morton WE (1995) Redefinition of abnormal susceptibility to environmental chemicals. Paper, given at the Second International Congress on Hazardous Waste. Atlanta

  39. Hahn M, Bonkovsky HL (1997) Multiple chemical sensitivity syndrome and porphyria. A note of caution and concern. Arch Intern Med 157(3):281–285

    Article  PubMed  CAS  Google Scholar 

  40. Mattern SE, Tefferi A (1999) Acute porphyria: the cost of suspicion. Am J Med 107(6):621–623

    Article  PubMed  CAS  Google Scholar 

  41. McDonagh AF, Bissell DM (1998) Porphyria and porphyrinology – the past fifteen years. Semin Liver Dis 18(1):3–15

    Article  PubMed  CAS  Google Scholar 

  42. Hoffer A (1963) The presence of malvaria in some mentally retarded children. Am J Ment Defic 67:730–732

    PubMed  CAS  Google Scholar 

  43. Sohler A, Renz RH, Smith S, et al. (1967) Significance of hydroxyskatole and mauve factor excretion in schizophrenia. Int J Neuropsychiatry 3(4):327–331

    PubMed  CAS  Google Scholar 

  44. O'Reilly PO, Ernest M, Hughes G (1965) The incidence of malvaria. Br J Psychiatry 111:741–744

    Article  PubMed  Google Scholar 

  45. Krischer K, Pfeiffer CC (1973) Biochemical relationship between kryptopyrrole (mauve factor and trans-3-methyl-2-hexenoic acid (schizophrenia odor). Res Commun Chem Pathol Pharmacol 5(1):9–15

    PubMed  CAS  Google Scholar 

  46. Walker JL (1975) Neurological and behavioral toxicity of kryptopyrrole in the rat. Pharmacol Biochem Behav 3(2):243–250

    Article  PubMed  CAS  Google Scholar 

  47. Wetterberg L, Formgren B (1976) Pharmacological and biochemical properties of kryptopyrrole and its oxidation products possibly related to acute intermittent porphyria. Ann Clin Res 8(Suppl 17):162–167

    PubMed  CAS  Google Scholar 

  48. Pfeiffer CC (1975) Mental and elemental nutrients. A physican's guide to nutrition and health care. Keats Publishing, New Canaan, Connecticut

  49. Prochazka E (2001) Pyrrolurie – das missing link? Umwelt Med Ges 14(4):284–285

    Google Scholar 

  50. Kamsteeg J (2002) HPU – eine angeborene Porphyrinopathie. Ztg Umweltmed 10(3):134–135

    Google Scholar 

  51. Kuklinski B (2004) Kryptopyrrolurie, nitrosativer Stress und Mitochondropathie. Nährstoff-News Nährstoff-Akademie Salzburg 3:5–8

    Google Scholar 

  52. Hessels J, van As S (2006) HPU: Hoe porfyrineonderzoek uit de hand liep. Een wetenschappelijke benadering. Ned Tijdschr Klin Chem Labgeneesk 31:58–64

    CAS  Google Scholar 

  53. van der Meer JW, van de Kerkhof R, The GK, et al. (2003) Hemopyrrollactamuria (HPU); from spots to pseudo-disease. Ned Tijdschr Geneeskd 147(36):1720–1721

    PubMed  CAS  Google Scholar 

  54. Pfeiffer CC (1987) Nutrition and mental illness. An orthomolecular approach to balancing body chemistry. Healing Arts Press, Rochester, Vermont

  55. Pauling L (1977) Vitamin homeostasis in the brain and megavitamin therapy. N Engl J Med 297(14):790–791

    Article  PubMed  CAS  Google Scholar 

  56. Pauling L (1975) Letter: Megavitamin therapy. Jama 234(2):149

    Article  PubMed  CAS  Google Scholar 

  57. Pauling L (1968) Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science 160(825):265–271

    Article  PubMed  CAS  Google Scholar 

  58. Hoffer A (1972) Orthomolecular treatment for schizophrenia. I. J Pract Nurs 22(8):16–19

    PubMed  CAS  Google Scholar 

  59. Pratt WA (1975) The orthomolecular approach to schizophrenia. J Am Osteopath Assoc 75(2):199–205

    PubMed  CAS  Google Scholar 

  60. RKI (2001) Mitteilung der Kommission „Methoden und Qualitätssicherung in der Umweltmedizin“ am Robert Koch-Institut (RKI). Grundsätze der Bewertung von umweltmedizinischen Methoden. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44:519–522

    Article  Google Scholar 

  61. EFSA – European Food Safety Authority (2006) Tolerable upper intake levels for vitamins and minerals. EFSA – European Food Safety Authority; Scientific Committee on Food; Scientific Panel on Dietetic Products, Nutrition and Allergies. http://www.efsa.eu.int

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Die (Krypto-)Pyrrolurie in der Umweltmedizin: eine valide Diagnose?. Bundesgesundheitsbl. 50, 1324–1330 (2007). https://doi.org/10.1007/s00103-007-0340-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00103-007-0340-5

Search

Navigation